Q4 2023 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2024-02-14 · accession 0001172661-24-001436
$586.7M
Reported value
34
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $70.6M | 12.0% | 3,703,433 | Common | SHARED |
| 23282W605 | CYTK | CYTOKINETICS INC | $41.7M | 7.11% | 500,000 | Common | SHARED |
| M96088105 | URGN | UROGEN PHARMA LTD | $39.3M | 6.70% | 2,620,545 | Common | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $33.0M | 5.63% | 1,823,184 | Common | SHARED |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $31.0M | 5.28% | 648,000 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $27.6M | 4.71% | 600,000 | Common | SHARED |
| 75382E109 | — | RAPT THERAPEUTICS INC | $27.3M | 4.66% | 1,099,753 | Common | SHARED |
| G01767105 | ALKS | ALKERMES PLC | $24.3M | 4.14% | 875,044 | Common | SHARED |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $23.5M | 4.00% | 1,037,690 | Common | SHARED |
| 92243G108 | PCVX | VAXCYTE INC | $22.6M | 3.85% | 360,000 | Common | SHARED |
| 30052C107 | EOLS | EVOLUS INC | $21.1M | 3.59% | 2,000,000 | Common | SHARED |
| 032724106 | ANAB | ANAPTYSBIO INC | $20.9M | 3.57% | 976,981 | Common | SHARED |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $20.0M | 3.41% | 293,000 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $19.3M | 3.28% | 994,229 | Common | SHARED |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $18.2M | 3.10% | 1,280,500 | Common | SHARED |
| 89157D105 | TRML | TOURMALINE BIO INC | $17.6M | 3.00% | 672,885 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA | $16.6M | 2.83% | 1,550,000 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $15.4M | 2.62% | 3,295,000 | Common | SHARED |
| 68404V100 | — | OPTINOSE INC | $11.4M | 1.94% | 8,839,939 | Common | SHARED |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $11.2M | 1.90% | 400,000 | Common | SHARED |
| 04335A105 | ARVN | ARVINAS INC | $9.6M | 1.64% | 234,082 | Common | SHARED |
| 48576A100 | — | KARUNA THERAPEUTICS INC | $9.6M | 1.63% | 30,250 | Common | SHARED |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $9.6M | 1.63% | 1,858,735 | Common | SHARED |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $8.5M | 1.45% | 1,309,975 | Common | SHARED |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $7.9M | 1.35% | 110,607 | Common | SHARED |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $7.7M | 1.31% | 80,000 | Common | SHARED |
| 457669307 | INSM | INSMED INC | $7.0M | 1.19% | 225,912 | Common | SHARED |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $4.7M | 0.81% | 1,093,273 | Common | SHARED |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $3.1M | 0.53% | 700,000 | Common | SHARED |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $2.7M | 0.46% | 125,000 | Common | SHARED |
| 03940C100 | ACLXGBX | ARCELLX INC | $2.7M | 0.46% | 48,264 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $550,000 | 0.09% | 20,000 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $395,005 | 0.07% | 4,963 | Common | SHARED |
| G63365103 | MURA | MURAL ONCOLOGY PUB LTD CO | $68,133 | 0.01% | 11,509 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.